Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - Gynaecological cancers

LBA32 - Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma

Date

17 Sep 2021

Session

Proffered Paper session - Gynaecological cancers

Presenters

Susana Banerjee

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

S. Banerjee1, P.B. Ottevanger2, A. Sarivalasis3, R. Le Scodan4, A. Montes5, J.R. Kroep6, M. Romeo Marin7, A. Casado Herraez8, M. Auvray-Kuentz9, A.M. Westermann10, B. Lucas11, D. Dangaj12, F. Herrera13, A. Wolfer3, C. Coens14, M.B. Vanlancker15, L. Kandalaft16, G. Coukos12

Author affiliations

  • 1 Gynaecology Department, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Medical Oncology, Radboud University Medical Center, 6525 GA - Nijmegen/NL
  • 3 Oncology, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 4 Oncology-radiotherapy, Ctre De Radiotherapie St Vincent, 35760 - St Gregoire/FR
  • 5 Medical Oncology, Guy's & St. Thomas' NHS Foundation Trust, SE19RT - London/GB
  • 6 Medical Oncology Department, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 7 Medical Oncology Department, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 8 Department Of Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 9 Oncology, APHP Hopital Europeen Georges Pompidou, 75015 - Paris/FR
  • 10 Medical Oncology Dept, Amsterdam University Medical Center (UMC) locatie Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 11 Oncologie, C.H.U. Brest - Hôpital Morvan, 29609 - Brest/FR
  • 12 Oncology, Ludwig Institute for Cancer Research - Lausanne Branch, 1066 - Epalinges/CH
  • 13 Immuno-oncology Department, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 14 Statistics, EORTC - European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 15 Medical Department, EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 16 Department Of Oncology, Center Of Experimental Therapeutics, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA32

Background

Anti-PD-1/L1 therapy alone has limited activity in ovarian cancer. We hypothesised that blockade of VEGF and prostaglandin E2 (PGE2) can reverse the endothelial barrier allowing T cell infiltration and subsequent T cell activation by PD-L1 blockade. This is the first trial combining an anti-PD-L1 antibody, atezolizumab (ATE), with bevacizumab (BEV) and the irreversible COX1/2 inhibitor acetylsalicylic acid (ASA).

Methods

Patients with platinum-resistant ovarian cancer (PROC) were randomised to 1) BEV(15mg/kg q3w) 2) ATE(1200mg q3w)+placebo(P) 3) ATE(1200mg q3w)+ASA(320mg/d) 4) BEV(15mg/kg q3w)+ATE(1200mg q3w)+P or 5) BEV(15mg/kg q3w)+ATE(1200mg q3w)+ASA(320mg/d) and treated until progression or unacceptable toxicity. Arms 2 and 3 were closed early following phase III results indicating insufficient activity of PD-L1 inhibitor monotherapy. Mandatory biopsies (pre-treatment and pre-cycle 3) and serial blood samples were collected. The primary endpoint was progression-free survival rate at 6 months (PFS-6). Secondary endpoints included tolerability, PFS, response rate (RR) and time to first subsequent therapy (TFST).

Results

122 patients were randomised: BEV(33); ATE+P(11); ATE+ASA(13); BEV+ATE+P(32); BEV+ATE+ASA(33). Median age 63 (36-82); 84% ≥3 prior therapies. 39/52 (75%) patients treated (Arms 1-3) crossed over at progression to BEV+ATE. PFS-6 rates (ITT) were 22%, 9%, 23%, 25% and 25% respectively. Median PFS were 2.3, 2.1 (HR 1.78, 0.89-3.58); 2.2 (HR 0.95, 0.49-1.85), 4.1 (0.84, 0.50-1.38), and 4.0 months (0.81, 0.49-1.34). RR: 10%, 0%, 9%, 19% and 15% respectively. Median TFST was longest in BEV+ATE containing arms (3.0, 2.4, 1.8, 5.3 and 5.8 months; P<0.001). Grade 3/4 treatment-related adverse events were 48%,10%, 36%, 32% and 30% respectively.

Conclusions

The addition of ASA to BEV+ATE did not improve efficacy. Relative to BEV or ATE(+/-ASA) arms, the BEV+ATE combinations numerically improved PFS and TFST and merits further exploration. Translational analyses are ongoing to identify biomarkers of clinical benefit.

Clinical trial identification

EudraCT 2015-004601-17 / NCT02659384.

Editorial acknowledgement

Legal entity responsible for the study

European Organisation for Research and Treatment of Cancer - EORTC.

Funding

EORTC with support from F. Hoffmann-La Roche Ltd.

Disclosure

S. Banerjee: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Invited Speaker: Clovis; Financial Interests, Personal, Advisory Board: Genmab; Financial Interests, Personal, Advisory Board: Immunogen; Financial Interests, Personal, Advisory Board: Mersana; Financial Interests, Personal, Advisory Board: Merck Sereno; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Tesaro; Financial Interests, Personal, Invited Speaker: Tesaro; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Research Grant: Tesaro; Non-Financial Interests, Principal Investigator, Phase II clinical trial Global lead: Verastem; Non-Financial Interests, Principal Investigator, ATARI phase II international trial (academic sponsored): Astrazeneca; Non-Financial Interests, Advisory Role: Epsilogen; Non-Financial Interests, Other, Member of membership committee: ESGO; Non-Financial Interests, Advisory Role, Medical advisor to UK ovarian cancer charity: Ovacome Charity; Non-Financial Interests, Other, Received research funding from UK based charity I have provided medical advice (non-remunerated): Lady Garden Foundation Charity. P.B. Ottevanger: Financial Interests, Institutional, Research Grant: Pharmamar. A. Sarivalasis: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Advisory Role: Tesaro; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Institutional, Research Grant: Roche. J.R. Kroep: Financial Interests, Personal, Advisory Role: VitroScan. L. Kandalaft: Financial Interests, Personal, Advisory Board: Geneos. G. Coukos: Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Boehringer-Ingelheim; Financial Interests, Personal, Advisory Role: Genentech; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Institutional, Research Grant: Iovance; Financial Interests, Institutional, Research Grant: Kite Pharma; Financial Interests, Personal, Advisory Role: NextCure; Financial Interests, Personal, Advisory Role: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.